31 May 2018
: Case report
A Case of Right-Sided Ulcerative Colitis with Mesalamine-Induced Hypersensitivity Reactions
Unusual clinical course, Challenging differential diagnosis, Diagnostic / therapeutic accidents, Adverse events of drug therapy
Haruka Hirono1ABCDEFG*, Kazuhiko Watanabe1D, Katsuhiko Hasegawa1D, Terasu Honma2D, Yoichi Ajioka3BD, Shogo Ohkoshi1ACDEFGDOI: 10.12659/AJCR.909644
Am J Case Rep 2018; 19:623-629
Abstract
BACKGROUND: Ulcerative colitis (UC) is a chronic inflammatory bowel disease, affecting the colon continuously from the rectum proximally. However, a clinical type with right-sided colitis sparing the anal side of the colon is also known. Mesalamine, which is generally used to treat UC, can rarely aggravate the disease.
CASE REPORT: A 56-year-old woman with no history of colonic diseases visited our hospital because of a positive fecal occult blood test. The first colonoscopy showed inflamed and edematous mucosa extending from the ascending colon to the right-half of the transverse colon. Colonic biopsy specimens demonstrated infiltrations of chronic inflammatory cells in the mucosa and crypt abscesses, but no epithelioid granulomas, compatible with UC. She was highly positive for PR3-ANCA, confirming the diagnosis of UC. After starting mesalamine, she had hypersensitivity reactions and aggravations of UC, which were confirmed endoscopically.
CONCLUSIONS: Right-sided colitis may be a subgroup of UC, and this is the first report of this type of disease complicated by aggravation due to mesalamine hypersensitivity.
Keywords: Antibodies, Antineutrophil Cytoplasmic, Colitis, Ulcerative, Colon, Ascending, Drug Hypersensitivity, Mesalamine
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947597
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.948156
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.948795
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947300
Most Viewed Current Articles
21 Jun 2024 : Case report
100,609
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
53,868
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
36,615
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
07 Jul 2023 : Case report
25,134
DOI :10.12659/AJCR.940200
Am J Case Rep 2023; 24:e940200